Catalent (NYSE:CTLT) – Research analysts at KeyCorp issued their Q3 2018 earnings per share estimates for shares of Catalent in a report issued on Wednesday. KeyCorp analyst D. Hooker forecasts that the company will post earnings per share of $0.36 for the quarter. KeyCorp currently has a “Overweight” rating and a $48.00 target price on the stock. KeyCorp also issued estimates for Catalent’s Q4 2018 earnings at $0.54 EPS, FY2018 earnings at $1.47 EPS and FY2019 earnings at $1.74 EPS.
CTLT has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of Catalent from a “buy” rating to a “hold” rating in a research report on Friday, March 9th. Royal Bank of Canada initiated coverage on shares of Catalent in a research report on Wednesday, December 13th. They set an “outperform” rating and a $46.00 price objective for the company. First Analysis initiated coverage on shares of Catalent in a research report on Friday, January 5th. They set an “equal weight” rating for the company. Finally, Goldman Sachs initiated coverage on shares of Catalent in a research report on Wednesday, January 24th. They set a “buy” rating and a $50.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Catalent has an average rating of “Buy” and an average target price of $45.83.
Catalent (NYSE:CTLT) last announced its quarterly earnings data on Monday, February 5th. The company reported $0.41 earnings per share for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. Catalent had a net margin of 3.03% and a return on equity of 23.85%. The business had revenue of $606.30 million during the quarter, compared to the consensus estimate of $565.05 million. During the same quarter in the prior year, the firm earned $0.27 EPS. The company’s revenue for the quarter was up 25.3% compared to the same quarter last year.
In other Catalent news, SVP William Downie sold 9,082 shares of the company’s stock in a transaction dated Thursday, March 8th. The shares were sold at an average price of $41.80, for a total value of $379,627.60. Following the completion of the transaction, the senior vice president now owns 46,986 shares in the company, valued at approximately $1,964,014.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 1.70% of the stock is currently owned by corporate insiders.
Several large investors have recently modified their holdings of CTLT. Nationwide Fund Advisors lifted its stake in shares of Catalent by 18.4% in the 3rd quarter. Nationwide Fund Advisors now owns 382,620 shares of the company’s stock worth $15,274,000 after acquiring an additional 59,528 shares during the period. New York State Common Retirement Fund lifted its stake in shares of Catalent by 4.2% in the 3rd quarter. New York State Common Retirement Fund now owns 885,466 shares of the company’s stock worth $35,348,000 after acquiring an additional 35,583 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Catalent by 14.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,694,801 shares of the company’s stock worth $67,657,000 after acquiring an additional 217,220 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Catalent by 24.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 62,242 shares of the company’s stock worth $2,484,000 after acquiring an additional 12,182 shares during the period. Finally, Pacer Advisors Inc. lifted its stake in shares of Catalent by 18.4% in the 3rd quarter. Pacer Advisors Inc. now owns 15,070 shares of the company’s stock worth $602,000 after acquiring an additional 2,342 shares during the period. 99.89% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by WKRB News and is the sole property of of WKRB News. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.wkrb13.com/2018/04/01/catalent-ctlt-expected-to-post-q3-2018-earnings-of-0-36-per-share.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.